Literature DB >> 2039214

Activity of a new carbapenem antibiotic, meropenem, against Haemophilus influenzae strains with beta-lactamase- and non-enzyme-mediated resistance to ampicillin.

J H Jorgensen1, L A Maher, A W Howell.   

Abstract

Meropenem was 8- to 32-fold more active (MIC for 90% of strains = 0.125 micrograms/ml) than imipenem against a collection of Haemophilus influenzae strains characterized as either susceptible to ampicillin or resistant to that agent by virtue of beta-lactamase or nonenzymatic mechanisms. MBCs and kinetic kill curve tests showed that meropenem (as well as imipenem, several cephalosporins, and amoxicillin-clavulanate) was bactericidal against all strains at or within four times the respective MICs. Thus, meropenem demonstrated greater inhibitory activity than imipenem and activity comparable to that of cefotaxime against these selected strains.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039214      PMCID: PMC245060          DOI: 10.1128/AAC.35.3.600

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Multicenter in vitro evaluation of SM-7338, a new carbapenem.

Authors:  R N Jones; K E Aldridge; S D Allen; A L Barry; P C Fuchs; E H Gerlach; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

2.  In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338.

Authors:  H C Neu; A Novelli; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

3.  In vitro activities and targets of three cephem antibiotics against Haemophilus influenzae.

Authors:  P M Mendelman; L L Henritzy; D O Chaffin; K Lent; A L Smith; T L Stull; E A Wiley
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

4.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

5.  Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; L A Maher; A W Howell
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

6.  Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae.

Authors:  P M Mendelman; D O Chaffin; T L Stull; C E Rubens; K D Mack; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

7.  In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I.

Authors:  J R Edwards; P J Turner; C Wannop; E S Withnell; A J Grindey; K Nairn
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

  7 in total
  6 in total

1.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

2.  Morphological changes and lysis induced by beta-lactams associated with the characteristic profiles of affinities of penicillin-binding proteins in actinobacillus pleuropneumoniae.

Authors:  T Inui; T Endo; T Matsushita
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

3.  Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.

Authors:  L Zerva; D J Biedenbach; R N Jones
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

Review 4.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

5.  Pharmacokinetics of meropenem in patients with intra-abdominal infections.

Authors:  A Bedikian; M P Okamoto; R K Nakahiro; J Farino; P N Heseltine; M D Appleman; A E Yellin; T V Berne; M A Gill
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

6.  In vitro activities of piperacillin against beta-lactamase-negative ampicillin-resistant Haemophilus influenzae.

Authors:  Yoshiro Morikawa; Miyoshi Kitazato; Junichi Mitsuyama; Shingo Mizunaga; Shinzaburo Minami; Yasuo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.